Results 61 to 70 of about 3,810 (184)

Terlipressin for Hepatorenal Syndrome: A Meta-Analysis of Randomized Trials

open access: yes, 2009
Background Hepatorenal syndrome (HRS) is a severe complication of end-stage renal disease whose management still constitutes a big challenge. Various approaches have been used for hepatorenal syndrome treatment, including vasoconstrictor therapy ...
Piergiorgio Messa   +7 more
core   +2 more sources

The HYSTER study: the effect of intracervically administered terlipressin versus placebo on the number of gaseous emboli and fluid intravasation during hysteroscopic surgery: study protocol for a randomized controlled clinical trial

open access: yesTrials, 2018
Background Transcervical resection of myoma or endometrium is a safe, hysteroscopic, minimally invasive procedure. However, intravasation of distension fluid is a common phenomenon during these procedures.
Lucilla E. Overdijk   +5 more
doaj   +1 more source

In vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V1 and V2

open access: yesJournal of Experimental Pharmacology, 2017
Khurram Jamil,1 Stephen Chris Pappas,2 Krishna R Devarakonda1 1Clinical Development, Mallinckrodt Pharmaceuticals, Bedminster, 2Orphan Therapeutics, LLC, Lebanon, NJ, USA Abstract: Terlipressin, a synthetic, systemic vasoconstrictor with selective ...
Jamil K, Pappas SC, Devarakonda KR
doaj  

Terlipressin for septic shock patients: a meta-analysis of randomized controlled study

open access: yesJournal of Intensive Care, 2019
Background Catecholamines are commonly used in septic shock but face limitations of their hypo-responsiveness and adverse events due to high dose. Terlipressin is a synthetic vasopressin analog with greater selectivity for the V1-receptor.
Yibing Zhu   +3 more
doaj   +1 more source

Systematic review: Terlipressin in acute oesophageal variceal haemorrhage

open access: yes, 2003
Background: Controversy exists surrounding pharmacological therapy in acute variceal bleeding. Methods: To determine the efficacy and safety of terlipressin.
Rockey, DC   +5 more
core   +1 more source

The Concise Guide to PHARMACOLOGY 2025/26: G protein‐coupled receptors

open access: yesBritish Journal of Pharmacology, Volume 182, Issue S1, Page S24-S151, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander   +206 more
wiley   +1 more source

A retrospective analysis of hyponatremia during terlipressin treatment in patients with esophageal or gastric variceal bleeding due to portal hypertension

open access: yesJGH Open, 2020
Background and Aim To explore the risk factors of hyponatremia caused by terlipressin. Methods Forty‐four patients with acute variceal bleeding treated with terlipressin from December 2016 to December 2018 were analyzed.
Xv Han   +4 more
doaj   +1 more source

The “dark” side of terlipressin: a case report of ischemic skin necrosis and review of literature

open access: yesEgyptian Liver Journal, 2023
Background Terlipressin is a commonly used drug in cirrhotic patients with acute variceal bleed (AVB) due to its vasoconstrictor effects. Ischemic complications are uncommon adverse events associated with worse outcomes.
Arpit Shastri   +4 more
doaj   +1 more source

The current applications and future directions of terlipressin. [PDF]

open access: yesHepatol Commun
Terlipressin is a vasopressin analog with potent splanchnic vasoconstrictor properties. It has an established role in managing portal hypertensive bleeding and hepatorenal syndrome-acute kidney injury, with a growing body of evidence demonstrating ...
Liu D, Testro A, Majumdar A, Sinclair M.
europepmc   +2 more sources

Terlipressin versus other vasoactive drugs for hepatorenal syndrome [PDF]

open access: yes, 2017
Background: Hepatorenal syndrome is defined as severe renal failure occurring in people with cirrhosis and ascites. Systematic reviews of randomised clinical trials found that, compared with placebo, terlipressin may reduce mortality and improve renal ...
Goldin, Alison H.   +14 more
core   +1 more source

Home - About - Disclaimer - Privacy